Incretin Receptor Biology Hub

GLP-1 agonists are among the most clinically validated peptide-class medicines in recent decades. This page explains the underlying biology, without promoting use.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

The incretin effect

The incretin effect is the observation that an oral glucose load produces a greater insulin response than an equivalent intravenous glucose load, because oral glucose stimulates the release of gut hormones — including GLP-1 and GIP — that potentiate insulin secretion. In type-2 diabetes the incretin effect is impaired, which is one of the rationales for incretin-receptor pharmacology.

Three receptors

• GLP-1 receptor (GLP-1R) — class B GPCR; expressed on pancreatic β-cells, GI tract, hypothalamus, heart, kidney.
• GIP receptor (GIPR) — class B GPCR; expressed on β-cells, adipocytes, bone, hypothalamus.
• Glucagon receptor (GCGR) — class B GPCR; expressed in liver, kidney, heart, adipocytes.

Pharmacology overview

Drug development in this class has progressed from single-receptor GLP-1 agonists (semaglutide, liraglutide) to dual agonists (tirzepatide — GIPR + GLP-1R) and triple agonists (retatrutide — GIPR + GLP-1R + GCGR). Each layer adds receptor coverage and complicates the pharmacology.

Human clinical relevance

• Type-2 diabetes glycaemic control — established.
• Body composition / weight reduction — established for some agents.
• Cardiovascular outcomes — established for some agents.
• Off-label and aesthetic uses — not established and outside scope.

Regulatory sensitivity

Prescription-only medicines in this class are tightly regulated in the UK. Public-facing advertising of POMs is restricted. See: POM advertising rules.

Not promotional

PeptideStacks describes this class for research-literacy purposes only. Decisions about whether a GLP-1 medicine is appropriate for an individual person belong with their clinician.